Shire shares slip as sales miss estimates in first full quarter with Baxalta

1 November 2016

Shire (LSE: SHP) has billed its third-quarter results as record-breaking, but markets are less convinced as the Ireland-incorporated company’s share price has dropped by 2.1% since the figures were presented on Tuesday.

Combined product sales increased by 110% compared to the third quarter of 2015, reaching $3.32 million, due to legacy Shire products and the inclusion of drugs from Baxalta in what was the first full quarter since Shire took over the company earlier this year in a $32 billion merger.

This was still 3% below the market consensus, according to analysts at investment bank Jefferies.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK